The relationship between bariatric surgery and erectile dysfunction is one of the better-documented findings in sexual medicine, and also one of the most frequently oversold. Men who undergo sleeve gastrectomy or Roux-en-Y gastric bypass often report meaningful improvement in erectile function within a year, and the pooled trial data supports that impression. But the same literature shows that a substantial minority of men see little change, that the degree of benefit depends heavily on what caused the dysfunction in the first place, and that surgery introduces a pharmacological complication rarely discussed in the pre-operative consultation: it permanently alters how oral medication is absorbed. Understanding all three of these points gives a far more accurate picture than the common framing of weight loss surgery as a sexual health cure.
Why Obesity Impairs Erectile Function in the First Place
Erection is a vascular event that depends on endothelial nitric oxide release, smooth muscle relaxation, and adequate arterial inflow. Obesity degrades each of these independently. Visceral adipose tissue is metabolically active, producing inflammatory cytokines that impair endothelial nitric oxide synthase activity and accelerate oxidative stress in the small arteries of the penis — vessels roughly one third the diameter of the coronary arteries, which is why erectile symptoms frequently precede cardiac symptoms by several years.
Obesity also drives a measurable endocrine shift. Adipose tissue expresses aromatase, which converts testosterone to estradiol, while elevated insulin suppresses sex hormone-binding globulin. The result is the pattern clinicians describe as obesity-induced hypogonadism: low total testosterone, low free testosterone, and a low-normal or suppressed luteinising hormone that distinguishes it from primary testicular failure. This condition is, importantly, largely reversible — which is the mechanistic basis for expecting improvement after significant weight loss.
Layered on top are the comorbidities that cluster with obesity: type 2 diabetes, hypertension, dyslipidaemia, and obstructive sleep apnoea. Each is an independent risk factor for erectile dysfunction, and each responds to weight loss at a different rate.
What the Surgical Outcome Data Actually Shows
The most useful quantitative summary comes from a systematic review and meta-analysis published in BMC Urology, which pooled eleven studies covering 370 men undergoing bariatric procedures [1]. Across those studies, the International Index of Erectile Function erectile function domain improved by a mean difference of 5.33 points (95% CI 4.12–6.54), with the total IIEF score improving by 7.21 points (95% CI 4.33–10.10). Sexual desire improved by 1.27 points and intercourse satisfaction by 2.57 points.
Context matters for interpreting those numbers. The IIEF erectile function domain runs from 1 to 30, and a change of roughly 4 points is generally considered the minimal clinically important difference for men with moderate dysfunction. A 5.33-point mean improvement therefore clears the threshold of clinical relevance, but not dramatically — and a mean conceals the spread. The confidence intervals in the pooled analysis are reasonably tight, but the underlying studies were small, mostly uncontrolled before-and-after designs, with follow-up typically between six and twenty-four months.
A 2025 systematic review and meta-analysis in The Journal of Sexual Medicine examined the desire component specifically and found a very large effect size for change in IIEF sexual desire following bariatric surgery (d = 1.22, 95% CI 0.41–2.03, P = 0.003), alongside comparable gains from dietary weight loss interventions [2]. The practical reading is that libido and satisfaction appear to respond at least as strongly as erectile capacity itself, which is consistent with a hormonal rather than a purely vascular mechanism.
Testosterone Recovery Is the Most Measurable Change
The endocrine response to surgical weight loss is the best-quantified outcome in this area. A meta-analysis in Andrology pooled 44 studies comprising 1,774 participants and compared testosterone gains from low-calorie dieting against bariatric surgery [3]. Total testosterone rose by a standardised mean difference of 2.5 nmol/L after dietary weight loss, but by 7.2 nmol/L (95% CI 6.0–8.4) after bariatric surgery. Free testosterone showed the same pattern, rising 19.9 pmol/L with dieting versus 58.0 pmol/L with surgery.
That is close to a threefold difference, and it tracks the magnitude of weight loss rather than the surgery itself. The same analysis found that men with higher baseline BMI and lower baseline SHBG and testosterone gained the most, which is intuitive: there is more suppression to reverse. Men over 40 gained relatively more total testosterone, while younger men gained relatively more free testosterone.
For a man whose erectile dysfunction is primarily driven by obesity-induced hypogonadism — low libido, poor morning erections, fatigue, and a testosterone level in the 7–10 nmol/L range — this is the mechanism by which surgery may support recovery of sexual function. For a man whose dysfunction is primarily vasculogenic or neuropathic, testosterone normalisation alone will not restore the hardware.
Why a Significant Minority of Men Do Not Improve
Several factors predict a blunted response. Long-standing type 2 diabetes causes structural damage to cavernosal smooth muscle and autonomic nerves that does not reverse with glycaemic improvement. Established atherosclerotic disease of the pudendal and cavernosal arteries represents fixed anatomical narrowing. Severe baseline dysfunction — an IIEF erectile function score below 11 — carries a poorer prognosis across virtually every ED intervention studied, surgical or pharmacological.
Psychological factors cut both ways. Rapid, dramatic weight loss changes body image, relationship dynamics, and sometimes relationship stability. The clinical literature on bariatric patients documents increased rates of relationship dissolution in the two years after surgery, and performance anxiety does not disappear simply because the scale reads lower. Nutritional deficiencies following malabsorptive procedures — particularly iron, B12, vitamin D, and zinc — can also independently contribute to fatigue and reduced sexual interest if not corrected.
The honest summary is that bariatric surgery improves the metabolic and hormonal substrate of erectile function, and clinical studies suggest most men experience measurable benefit, but it is not a targeted treatment for erectile dysfunction and should not be chosen as one.
The Absorption Problem Nobody Mentions Before Surgery
This is the most practically important and least discussed consequence. Bariatric procedures, particularly Roux-en-Y gastric bypass, deliberately alter gastric volume, gastric pH, intestinal transit time, and the surface area available for absorption. A review in Obes Facts examining oral drug performance after bariatric surgery concluded that bioavailability can be affected by the altered solubility and pH of the gastrointestinal environment and by the loss of gastrointestinal transporters, and that each drug must be evaluated individually with respect to its site and mechanism of absorption [4].
Oral PDE5 inhibitors are directly exposed to this problem. Sildenafil, tadalafil, and vardenafil are all absorbed primarily in the proximal small intestine and undergo substantial first-pass hepatic metabolism. A procedure that reduces gastric acid, shortens the absorptive segment, and accelerates transit can plausibly reduce peak plasma concentration and delay time to peak — which, for an on-demand medication, is the difference between a usable response and an apparent treatment failure. Men who report that the same dose of an oral PDE5 inhibitor stopped working after their surgery are often describing a pharmacokinetic problem rather than a worsening of their underlying condition.
Sublingual administration is the established workaround for this class of problem, because the drug crosses the oral mucosa into the systemic circulation and bypasses both the altered gut and first-pass hepatic metabolism. Sublingual apomorphine, a centrally acting dopamine agonist, is the most studied example in sexual medicine: a Cochrane-style systematic review of nine randomised controlled trials found it produced 6–27% more successful intercourse attempts than placebo and remains the only licensed oral ED agent not absolutely contraindicated with nitrates [5]. An earlier Phase III dose-optimisation study in 849 men reported attempts resulting in intercourse rising from 12.7% at baseline to 38.3% on treatment, with a median time to erection of 23 minutes [6]. Preclinical work has further shown that apomorphine potentiates PDE5-inhibitor-induced erection without producing an additional drop in systemic blood pressure, suggesting the central and peripheral mechanisms are complementary rather than redundant [7].
Conclusion
Bariatric surgery and erectile dysfunction are genuinely linked, and the direction of the effect is favourable: pooled data shows a clinically meaningful IIEF improvement of roughly five points, driven substantially by a threefold greater testosterone recovery than dieting achieves. But the benefit is partial, slower than most men expect, and largely absent in those with established diabetic or atherosclerotic damage. Post-surgical men who still require pharmacological support also face an absorption environment that has been structurally changed, which makes route of administration a legitimate clinical variable rather than a marketing detail. Anyone in this situation should have erectile function formally assessed, testosterone and nutritional status measured, and treatment selected with the altered gastrointestinal anatomy explicitly in mind. See more clinical articles on the OnyxMD blog.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com, including VAST, a sublingual formulation combining apomorphine with tadalafil and vardenafil.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Liu S, Cao D, Ren Z, Li J, Peng L, Zhang Q, et al. The relationships between bariatric surgery and sexual function: current evidence based medicine. BMC Urology. 2020;20(1):150. doi:10.1186/s12894-020-00707-1
Biernikiewicz M, Rusiecka A, Kalka D. Obesity and sexual desire: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2025;22(5):677-693. doi:10.1093/jsxmed/qdaf057
Ken-Dror G, Fluck D, Fry CH, Han TS. Meta-analysis and construction of simple-to-use nomograms for approximating testosterone levels gained from weight loss in obese men. Andrology. 2024;12(2):297-315. doi:10.1111/andr.13484
Schlatter J. Oral contraceptives after bariatric surgery. Obesity Facts. 2017;10(2):118-126. doi:10.1159/000449508
Guillen V, Rueda JR, Lopez-Argumedo M, Sola I, Ballesteros J. Apomorphine for the treatment of erectile dysfunction: systematic review and meta-analysis. Archives of Sexual Behavior. 2020;49(8):2963-2979. doi:10.1007/s10508-020-01817-5
Mulhall JP, Bukofzer S, Edmonds AL, George M. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clinical Therapeutics. 2001;23(8):1260-1271. doi:10.1016/s0149-2918(01)80105-3
Park JY, Son H, Kim SW, Paick JS. Potentiation of apomorphine effect on sildenafil-induced penile erection in conscious rabbits. Asian Journal of Andrology. 2004;6(3):205-209. PMID:15273868
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.